Introduction to Predictive Biomarkers: Definitions and Characteristics
The concept of “biomarkers” as indicators of health or disease is not new. This introductory chapter is focused on the utilization of “biomarkers” that can be detected directly in tissues from cancer patients. Within this context, biomarkers include proteins and nucleic acids and derivatives and parts thereof. The main methods of biomarker detection in cancer are reviewed, together with definitions and requirements set forth by regulatory organizations. The major challenges that this constellation of new test modalities presents to pathologists and clinicians are discussed, along with critical aspects of test cost and resultant test availability.
“Precision” or “personalized medicine” appears to be an irresistible force, in turn requiring a new level of “precision pathology.” This enhanced level of assay performance may only be achieved by further refinement and development of the methods, following approaches described in this opening chapter. Already these new performance demands have radically changed the practice of pathology, particularly with reference to the diagnosis and management of malignant disease. Today we stand only at the end of the beginning of a new era of pathology practice; the ultimate end none of us as yet can foresee.
KeywordsCompanion diagnostic Precision medicine Biomarkers Predictive biomarkers Immunohistochemistry In situ proteomics Quantifiable internal reference standards Immunohistochemistry controls Digital pathology Cancer diagnosis
- 1.Van den Tweel J, Jiang J, Taylor CR. From magic to molecules: an illustrated history of disease: Beijing University Press; 2016.Google Scholar
- 3.Cheung CC, D’Arrigo C, Dietel M, et al.; From the International Society for Immunohistochemistry and Molecular Morphology (ISIMM) and International Quality Network for Pathology (IQN Path). Evolution of quality assurance for clinical immunohistochemistry in the era of precision medicine: part 4: tissue tools for quality assurance in immunohistochemistry. Appl Immunohistochem Mol Morphol. 2017;25: 227–230.CrossRefGoogle Scholar
- 4.Nass SJ, Phillips J, Patlak. Policy issues in the development and adoption of biomarkers for molecularly targeted cancer therapies. National Cancer Policy Forum. Workshop Summary. The National Academies Press. 2015. NAP.edu/10766.Google Scholar
- 5.European Parliament. Directive 98/79/EC of the European Parliament and of the Council of 27 October 1998 on in vitro diagnostic medical devices. 1998. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:1998:331:0001:0037:EN:PDF.
- 6.U.S. Food and Drug Administration. List of cleared or approved companion diagnostic devices (in vitro and imaging tools). 2016. Other nucleic acid based tests are listed separately under an included link. Updated 6/09/16. http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/ucm301431.htm.
- 7.U.S. Food and Drug Administration. Guidance for industry and FDA staff. In vitro diagnostic (IVD) device studies – frequently asked questions. 2010. http://www.fda.gov/downloads/MedicalDevices/.../ucm071230.pdf.